Funding for this research was provided by:
Japan Society for the Promotion of Science (20K10480)
Japan Agency for Medical Research and Development (21ek0410086h0001)
Article History
Received: 4 November 2021
Accepted: 13 May 2022
First Online: 10 June 2022
Declarations
:
: This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Informed consent was not applicable for this study, based on the ethical guidelines for medical and health research involving human subjects issued by the Ministry of Health, Labor and Welfare and Ministry of Education, Culture, Sports, Science and Technology of Japan (revised on February 28, 2017). This study was approved by the ethics committee of Tokyo Women’s Medical University (approval number: 4910).
: Not applicable.
: Tokyo Women’s Medical University (TWMU), particularly the Division of Multidisciplinary Management of Rheumatic Diseases, Department of Rheumatology, has received unrestricted research grants from the following companies: Ayumi Pharmaceutical Co.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Nippon Kayaku Co., Ltd.; Taisho Toyama Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; and Teijin Pharma Ltd., with which TWMU paid the salaries of RS.MH has received research grants from the following companies: AbbVie Japan GK; Asahi Kasei Corp.; Astellas Pharma Inc.; Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co.; Daiichi-Sankyo, Inc.; Eisai Co., Ltd.; Kissei Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Nippon Kayaku Co., Ltd.; Sekisui Medical; Shionogi & Co., Ltd.; Taisho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. MH has received speaker fees from the following companies: AbbVie Japan GK Ayumi Pharmaceutical Co.; Boehringer-Ingelheim Japan, Inc.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Kissei Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. MH is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd., and Teijin Pharma.ET has received lecture/consulting fees from the following: Abbvie; Asahi Kasei Pharma Co.; Astellas Pharmaceutical; Ayumi Pharmaceutical; Chugai Pharmaceutical; Eisai Pharmaceutical; Eli Lilly Japan K.K.; GlaxoSmithKline K.K.; Kyowa Pharma Chemical Co., Ltd.; Janssen Pharmaceutical K.K.; Mochida Pharmaceutical Co., Ltd.; Pfizer, Takeda Pharmaceutical; and Teijin Pharma Ltd.